A new skin laxity scale for the buttocks: the Skin Laxity Visual Scale (SLVS).

Background: The Skin Laxity Severity Scale for the buttocks was previously developed to separately assess buttock ptosis, a scalloped appearance of the skin, infragluteal fold, localized fat on the lower third of the buttocks, and linear depressed lesions. A more objective, faster and shorter version of this scale, to be evaluated visually, would be more feasible to apply in daily practice.

Objectives: To present a new skin laxity scale for the buttocks: the Skin Laxity Visual Scale (SLVS).

Buttocks' Skin Laxity Severity Scale.

Background: Clinical scales are useful to assess skin laxity in different areas of the body.

Objective: To elaborate and validate a photonumeric scale to assess buttocks skin laxity.

Materials And Methods: The Buttocks' Skin Laxity Severity Scale (SLSS) was developed based on a sample of 120 patients.

Effects of different doses of abobotulinumtoxinA for the treatment of anterior gingival smile.

Botulinum toxin type A (BoNT-A) is an easy and fast treatment for gingival smile (GS). The objective of the study was to compare the reduction of gingival exposure using three different doses of abobotulinumtoxinA (ABO) in patients with different severities of anterior GS, and to assess treatment safety and patients' satisfaction. A prospective, single-center, randomized, double-blind study was conducted.

Fields of anhidrotic effects of abobotulinumtoxinA in patients with compensatory hyperhidrosis.

Background: Botulinum toxin type A can be used to treat compensatory hyperhidrosis (CHH), which presents areas of different intensity of sweating. More information about the anhidrotic effects is needed.

Objective: To evaluate the fields of anhidrotic effects (FAEs) resulting from different doses (5 and 10 U), dilution, and depths of injection of abobotulinumtoxinA in patients with CHH.

Fields of muscular and anhidrotic effects of 2 botulinum toxin-A commercial preparations: a prospective, double-blind, randomized, multicenter study.

Background: Longevity of effects and dose equivalence of different botulinum toxin type A (BoNT-A) preparations need to be better clarified because BoNT-A units are manufacturer-specific. These points are of particular importance for new brands emerging in the market.

Objective: To assess the field of muscular and anhidrotic effects of 2 commercial preparations of BoNT-A (incobotulinumtoxinA: Xeomin [XEO]; abobotulinumtoxinA: Dysport [DYS]) administered to the upper third of the face.

Objective assessment of erythema and pigmentation of melasma lesions and surrounding areas in long-term management regimens with triple combination.

Background: Melasma has a negative impact on quality of life since it typically occurs on the face.

Objectives: To evaluate the erythema and pigmentation of melasma lesions and the surrounding areas in patients receiving triple combination (TC: hydroquinone, tretinoin, and fluocinolone acetonide) regimens.

Methods: Patients first received an 8-week daily TC treatment and were then randomized to twice weekly or tapering regimen with TC.

Superficial dermabrasion versus topical tretinoin on early striae distensae: a randomized, pilot study.

Background: Striae distensae (SD) is a common skin condition, with a prevalence ranging from 40% to 90%, depending on the population studied.

Objectives: To evaluate the efficacy of superficial dermabrasion and compare it with that of topical tretinoin cream in the treatment of narrow and early SD.

Materials And Methods: Prospective, single-center, randomized, open-label study.

Quality of life and satisfaction of patients after full-face injections of abobotulinum toxin type A: A randomized, phase IV clinical trial.

Background: Although botulinum toxin type A (BoNT-A) has been used effectively and safely to reduce facial dynamic wrinkles, few studies assessed patients' quality of life and satisfaction after treatment.

Objective: To assess the quality of life and satisfaction of patients treated with full-face injections of variable doses of abobotulinum toxin A (ABO).

Methods: Ninety subjects were randomized into 3 different groups, receiving 120-165 U, 166-205 U and 206-250 U, respectively.

Full-face injections of variable total doses of abobotulinum toxin type A: A randomized, phase IV clinical trial of safety and efficacy.

Background: Botulinum toxin type A (BoNT-A) has been used for almost 20 years in cosmetic dermatology to reduce dynamic wrinkles on single or multiple facial areas.

Objective: To evaluate the safety and efficacy of full-face treatments with various total doses of abobotulinum toxin A (ABO).

Methods: A total of 90 participants were enrolled.

Impact of a cybertutor in dermatological teaching.

Background: The potential value of multimedia programs as an accessory instrument for medical education has already been demonstrated in several areas. However, most of them lack adequate validation. The authors proposed this study in order to develop and evaluate a computer multimedia program, aiming at providing a more attractive and state of the art learning tool in dermatology.

Double-blind, randomized, controlled clinical trial to compare safety and efficacy of a metallic cannula with that of a standard needle for soft tissue augmentation of the nasolabial folds.

Background: Injection-related side effects and complications are likely to occur during or after filler injections; they are mainly caused by the injection technique.

Objective: To assess safety and efficacy of a metallic cannula to inject hyaluronic acid (HA) filler in the nasolabial folds and to compare the safety of this cannula with that of a standard needle.

Methods: This was a prospective, randomized, phase II, double-blinded study that included 25 participants with Grade 2 to 3 for bilateral nasolabial folds according to the Modified Fitzpatrick Wrinkle Scale (MFWS).

Field effect of two commercial preparations of botulinum toxin type A: a prospective, double-blind, randomized clinical trial.

Background: The dose equivalence of commonly used commercial preparations of botulinum toxin type A, Dysport (abotulinumtoxinA [ABO] 500 U, Ipsen Biopharm Limited, Wrexham, United Kingdom) and Botox (onabotulinumtoxinA [ONA] 100 U, Allergan, Irvine, CA), remains unclear.

Objective: We sought to evaluate the field effect for ABO and ONA at dose equivalences of 2.5:1.

Cosmeceuticals for cellulite.

Cellulite is characterized by alterations to the skin surface, presenting as dimpled or puckered skin of the buttocks and posterior and lateral thighs. It mainly affects women. Cellulite occurrence is believed to be due to structural, inflammatory, morphological and biochemical alterations of the subcutaneous tissue.

Cybertutor: a teaching tool in Dermatology.

It was developed a teaching tool in Dermatology for undergraduate medical students, using an interactive website, the Cybertutor. Clinical cases, lectures and updated bibliography were selected. Photographies of dermatological lesions were taken from ambulatory patients.

Side-by-side comparison of areas with and without cellulite depressions using magnetic resonance imaging.

Background: Cellulite is characterized by alterations in the relief of the skin surface. Magnetic resonance imaging (MRI) is recognized as a reliable technique for measuring adipose volume according to body site and for the visualization of the subcutaneous structures.

Objective: To compare subcutaneous tissue in areas with and without cellulite on the buttocks of same subjects using a noninvasive technique.